Atossa Therapeutics Inc (ATOS)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.60-4.41%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Atossa Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.863
Annual ending 2026-12-31
Revenue	—	54.46M
EPS	—	-3.747
Annual ending 2027-12-31
Revenue	—	82.35M
EPS	—	-2.783

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage capital allocation through equity offerings	It raised capital through equity offerings to support operations.	Intact	fails to raise sufficient capital to sustain operations through FY26	Qualitative: Capital raised via $4.5M offering and CVR issuance June $4.5M registered direct offering and October stapled CVR issuance confirm active capital allocation and balance sheet strengthening. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Resolve patent disputes through settlement agreements	Atossa is working to settle patent disputes and clarify its strategy in 2026.	Recovered	patent disputes remain unresolved or escalate through FY26	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Convert strategic clarity into measurable progress in 2026	A primary condition in Atossa Therapeutics Inc's published investment case. The stated target is show measurable progress on strategic goals throughout FY26.	Improving	fails to show measurable strategic progress throughout FY26	Qualitative progress: 2 earnings beats, CVR issuance, but $4.5M dilution Q1/Q2 earnings beats, CVR issuance, $4.5M stock offering, and clinical development challenges reported in 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 3
2026-07-25	Unavailable	Unavailable	2 / 3
2026-07-26	Unavailable	Unavailable	2 / 3
2026-07-27	Unavailable	Unavailable	2 / 3
2026-07-28	Unavailable	Unavailable	1 / 3
2026-07-29	Unavailable	Unavailable	1 / 3
2026-07-30	Unavailable	Unavailable	1 / 3
2026-07-31	Unavailable	Unavailable	1 / 3
2026-08-01	Unavailable	Unavailable	1 / 3
2026-08-02	Unavailable	Unavailable	1 / 3
2026-08-03	Unavailable	Unavailable	1 / 3
2026-08-04	Unavailable	Unavailable	1 / 3
2026-08-05	Unavailable	Unavailable	1 / 3
2026-08-06	Unavailable	Unavailable	1 / 3
2026-08-07	Unavailable	Unavailable	2 / 3
2026-08-08	Unavailable	Unavailable	1 / 3
2026-08-09	Unavailable	Unavailable	1 / 3
2026-08-10	Unavailable	Unavailable	1 / 3
2026-08-11	Unavailable	Unavailable	1 / 3
2026-08-12	Unavailable	Unavailable	1 / 3
2026-08-13	Unavailable	Unavailable	1 / 3
2026-08-14	Unavailable	Unavailable	2 / 3
2026-08-15	Unavailable	Unavailable	2 / 3
2026-08-16	Unavailable	Unavailable	2 / 3
2026-08-17	Unavailable	Unavailable	2 / 3
2026-08-18	Unavailable	Unavailable	2 / 3
2026-08-19	Unavailable	Unavailable	2 / 3
2026-08-20	Unavailable	Unavailable	2 / 3
2026-08-21	Unavailable	Unavailable	2 / 3
2026-08-22	Unavailable	Unavailable	2 / 3
2026-08-23	Unavailable	Unavailable	2 / 3
2026-08-24	Unavailable	Unavailable	2 / 3
2026-08-25	Unavailable	Unavailable	2 / 3
2026-08-26	Unavailable	Unavailable	2 / 3
2026-08-27	Unavailable	Unavailable	2 / 3
2026-08-28	Unavailable	Unavailable	2 / 3
2026-08-29	Unavailable	Unavailable	2 / 3
2026-08-30	Unavailable	Unavailable	2 / 3
2026-08-31	Unavailable	Unavailable	2 / 3
2026-09-01	Unavailable	Unavailable	2 / 3
2026-09-02	Unavailable	Unavailable	2 / 3
2026-09-03	Unavailable	Unavailable	2 / 3
2026-09-04	Unavailable	Unavailable	2 / 3
2026-09-05	Unavailable	Unavailable	2 / 3
2026-09-06	Unavailable	Unavailable	2 / 3
2026-09-07	Unavailable	Unavailable	2 / 3
2026-09-08	Unavailable	Unavailable	2 / 3
2026-09-09	Unavailable	Unavailable	2 / 3
2026-09-10	Unavailable	Unavailable	2 / 3
2026-09-11	Unavailable	Unavailable	2 / 3
2026-09-12	Unavailable	Unavailable	2 / 3
2026-09-13	Unavailable	Unavailable	2 / 3
2026-09-14	Unavailable	Unavailable	2 / 3
2026-09-15	Unavailable	Unavailable	2 / 3
2026-09-16	Unavailable	Unavailable	2 / 3
2026-09-17	Unavailable	Unavailable	2 / 3
2026-09-18	Unavailable	Unavailable	2 / 3
2026-09-19	Unavailable	Unavailable	2 / 3
2026-09-20	Unavailable	Unavailable	2 / 3
2026-09-21	Unavailable	Unavailable	2 / 3
2026-09-22	Unavailable	Unavailable	2 / 3
2026-09-23	Unavailable	Unavailable	2 / 3
2026-09-24	Unavailable	Unavailable	2 / 3
2026-09-25	Unavailable	Unavailable	2 / 3
2026-09-26	Unavailable	Unavailable	2 / 3
2026-09-27	Unavailable	Unavailable	2 / 3
2026-09-28	Unavailable	Unavailable	2 / 3
2026-09-29	Unavailable	Unavailable	2 / 3
2026-09-30	Unavailable	Unavailable	2 / 3
2026-10-01	Unavailable	Unavailable	2 / 3
2026-10-02	Unavailable	Unavailable	2 / 3
2026-10-03	Unavailable	Unavailable	2 / 3
2026-10-04	Unavailable	Unavailable	2 / 3
2026-10-05	Unavailable	Unavailable	2 / 3
2026-10-06	Unavailable	Unavailable	2 / 3
2026-10-07	Unavailable	Unavailable	2 / 3
2026-10-08	Unavailable	Unavailable	2 / 3
2026-10-09	Unavailable	Unavailable	2 / 3
2026-10-10	Unavailable	Unavailable	2 / 3
2026-10-11	Unavailable	Unavailable	2 / 3
2026-10-12	Unavailable	Unavailable	2 / 3
2026-10-13	Unavailable	Unavailable	2 / 3
2026-10-14	Unavailable	Unavailable	2 / 3
2026-10-15	Unavailable	Unavailable	2 / 3
2026-10-16	Unavailable	Unavailable	2 / 3
2026-10-17	Unavailable	Unavailable	2 / 3
2026-10-18	Unavailable	Unavailable	2 / 3
2026-10-19	Unavailable	Unavailable	2 / 3
2026-10-20	Unavailable	Unavailable	2 / 3
2026-10-21	Unavailable	Unavailable	2 / 3
2026-10-22	Unavailable	Unavailable	2 / 3
2026-10-23	Unavailable	Unavailable	2 / 3
2026-10-24	Unavailable	Unavailable	2 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	3	0	0
2026-06-01	3	0	0
2026-07-01	2	0	0
2026-08-01	2	0	0
2026-09-01	2	0	0
2026-10-01	2	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Resolve patent disputes through settlement agreementsQualitative condition

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

1 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.0%Typical daily move · historical

Downside history

-87.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Atossa Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative development-stage biotechnology business, not a proven compounder. The long-term thesis is in a watch state: recent signals improved mildly, but confidence is low and the company remains loss-making with high risk.

What's priced into Atossa Therapeutics Inc

The evidence does not provide a valuation measure or clear account of what the market already assumes, so whether ATOS is cheap or expensive versus peers cannot be assessed. The recent decline in share performance alongside results below the industry cohort suggests expectations may be cautious, but the evidence is limited.

What the fundamentals likely do

Over the multi-year view, progress depends on advancing (Z)-endoxifen in oncology and rare diseases; trial enrollment was completed in 2026-Q2, and management has kept this priority for two quarters. Equity offerings raised $4.5 million upfront in that quarter, with potential total proceeds of $16.5 million, while the business remains loss-making. Near term, the recent earnings beat is positive, but a smaller company in a high-miss-rate industry faces meaningful risk at its next report.

What Atossa Therapeutics Inc hinges on

The thesis hinges on continued development progress and whether the clinical program can move forward while the company supports its work with available capital. A guidance cut would be a negative signal, while weaker employment data could weigh on cyclical healthcare names; continued strength among sector bellwethers could support sector sentiment. These external signals are not proof of ATOS-specific progress.